Add To Watchlist

LILLY

The Wire

Eli Lilly head of research, development to retire

Eli Lilly & Co. said Friday its science and technology head will retire. The drugmaker hired the chief researcher at AstraZeneca PLC to replace him.

AG says Utah agrees to $24M Zyprexa settlement

Utah has agreed to a $24 million settlement with Eli Lilly & Co. over claims the drugmaker engaged in off-label marketing of the anti-psychotic drug Zyprexa, Utah Attorney General Mark Shurtleff said Wednesday.

APNewsBreak: SC AG reaches $45M deal with Lilly

South Carolina's attorney general said Friday the state has reached a $45 million settlement with drug maker Eli Lilly & Co. over the company's marketing of an anti-psychotic drug, an agreement the drug maker said was its largest with a single state over Zyprexa.

Eli Lilly CEO banking on new drug pipeline

There are some life experiences few will ever have. And as the oldest of nine children and CEO of a Fortune 500 company, John Lechleiter has a couple under his belt.

Lilly posts 3Q profit; analysts doubt future sales

Eli Lilly & Co. turned a third-quarter profit as sales volume on several drugs climbed, but its newest drug and a possible key source of future revenue started slowly.

Lilly to cut 14 pct of staff, trim $1B in costs

Seeking to cut costs and bring new drugs to market more quickly as its best-sellers go off-patent, drugmaker Eli Lilly & Co. said Monday it will eliminate 5,500 jobs over two years and reorganize into five business units.

Patent ruling on Lilly drug stirs some surprise

A federal court ruling that invalidated a patent protecting Eli Lilly and Co.'s cancer drug Gemzar surprised at least one analyst covering the company but stirred little reaction from investors in trading Tuesday.

Cubs' Lilly goes on DL

The Cubs placed left-hander Ted Lilly on the 15-day disabled list on Saturday because of inflammation in his pitching shoulder.

Eli Lilly 2Q profit rises but shares lag behind

Eli Lilly and Co.'s second-quarter profit rose 21 percent but the drugmaker's share price lagged Wednesday, as investors wait to learn more about how the company will handle a daunting revenue hole that looms a few years away.

FDA clears Eli Lilly's blood thinner Effient

The Food and Drug Administration on Friday approved a highly anticipated blood thinner from Eli Lilly, though the drug must carry the agency's sternest warning because of its bleeding risks.

Consumer group wants halt on review of Lilly drug

Consumer health advocates and a co-developer of a highly anticipated blood thinner from Eli Lilly are calling on the Food and Drug Administration to halt its review of the drug, which they say may be unsafe at the suggested dose.

Lilly 1Q profit rises on higher sales; stock falls

Drugmaker Eli Lilly and Co. saw its first-quarter profit soar on strong sales but then watched its stock price dip Monday on a rough day for the broader market.

FDA admits error in barring doctor from panel

An influential cardiologist who criticized an experimental Eli Lilly drug should not have been barred from a panel that evaluated the drug's safety, federal health officials said.

Plump pension awaits former Eli Lilly leader

Former Eli Lilly & Co. Chairman and Chief Executive Sidney Taurel saw his total pay flatten out during his last year on the job, but retirement nest eggs totaling more than $40 million are waiting for him, according to regulatory filings.

FDA panel unanimously backs Lilly blood thinner

A panel of government health experts said Tuesday a highly anticipated Eli Lilly blood thinner marks a significant advance over older treatments and should be approved.

Will Kate and Sawyer be an item again on 'Lost'?

If you thought the tortured tropical romance between Sawyer and Kate was over, you might be surprised by a future episode of "Lost," according to Evangeline Lilly, who stars as Kate on the ABC thriller.

Drugmaker Lilly enters guilty plea in Zyprexa case

The U.S. Attorney's Office for the Eastern District of Pennsylvania says drugmaker Eli Lilly & Co. formally pleaded guilty to a misdemeanor tied to the marketing of its top-seller, the anti-psychotic Zyprexa.

FDA: Eli Lilly blood thinner has clear benefits

Federal health officials said Friday a blood thinner from Eli Lilly offers life-saving benefits over drugs currently on the market, though its use may have to be restricted due to bleeding side effects.

Eli Lilly reports 4Q loss but beats forecasts

Drugmaker Eli Lilly & Co. beat Wall Street's fourth-quarter expectations Thursday, but analysts say they're waiting for a regulatory hearing next week to gauge the company's near-term health.

Lilly settles Zyprexa suit for $1.42 billion

Eli Lilly & Co. taught its sales force a catchy slogan to peddle the antipsychotic drug Zyprexa for treating the elderly.

Lilly nears $1.4B Zyprexa agreement, report says

Drugmaker Eli Lilly and Co. is close to agreeing to a $1.4 billion settlement related to a government investigation into the marketing of its top seller Zyprexa, according to a New York Times report.

Lilly to post 2008 loss on ImClone costs

Eli Lilly and Co. said Thursday its $6.5 billion ImClone acquisition will wipe out its 2008 profit and dent next year's earnings as well.

Lilly withdraws Cymbalta chronic pain application

Drugmaker Eli Lilly and Co. withdrew an application to have its antidepressant Cymbalta approved as a treatment for chronic pain, but the company said Friday it will apply again in 2009.

Eli Lilly posts 3Q loss but eyes more growth

Fresh off the biggest deal in company history, drugmaker Eli Lilly and Co. may not be done shopping, Chief Executive John Lechleiter said Thursday.

Lilly takes $1.4B charge related to investigation

Eli Lilly and Co. will take a big bite out of its third-quarter earnings with a $1.4 billion charge related to a government investigation over marketing practices for the anti-psychotic Zyprexa.

The Vine
Lilly Sold Drug for Dementia Knowing It Didn't Help, Files Show
Source: Bloomberg.com

June 12 (Bloomberg) -- Eli Lilly & Co.

Who's Really the Bad Guy? Kevin Trudeau or the Companies He's Exposing?

Ok. Kevin Trudeau is a business man who's decided that his business is a) exposing harmful practices (engaged in by big business and the government - risky business right there) and,

Man's Best Friend Stolen From Van
Source: wbbm780.com

Gene Voss, 64, said his 13-year-old black Labrador, Lilly, was inside his dark green 2001 Chevrolet Venture minivan when it was stolen at about 9:15 a.m. Wednesday from outside his dry cleaning business, One-Hour Martinizing at 215 E. Ogden Ave. in Naperville.

Counterfeit medicines: the pills that kill
Source: Telegraph

Fake pharmaceutical drugs - whether sold directly over the internet or infiltrated into the neighbourhood pharmacy or local hospitals - have become a huge and fast-increasing threat. In 2005, 500,000 single doses of fake medicines were discovered across Europe.

Lilly in Settlement Talks With U.S.
Source: The New York Times

A settlement of an inquiry into Lilly's marketing of the antipsychotic drug Zyprexa could result in the company's paying more than $1 billion to federal and state governments.

Calif. autism rate grows despite mercury-free vaccines - The Boston Globe
Source: The Boston Globe

Dr. Daniel Geschwind, a neurologist at the David Geffen School of Medicine at the University of California, Los Angeles, said the focus now should be on searching for the causes of autism, such as possible genetic links.

Christmas Without Jonathan - washingtonpost.com
Source: The Washington Post

They long to see him walk through the door of his family's home in Vienna -- muscular, dark-eyed, big-hearted Jonathan. The combat medic. The oldest son.

F.D.A. Issues Strictest Warning on Two Diabetes Drugs
Source: The New York Times

The agency has called for the toughest safety warning on Avandia and Actos, whose risks have become a focus of concern.

Judge Criticizes Reporter in Lilly Case
Source: The New York Sun

A federal judge criticizes how a New York Times reporter went about getting documents regarding Eli Lilly's anti-psychotic drug, Zyprexa.

Drug Files Show Maker Promoted Unapproved Use
Source: The New York Times

Eli Lilly pushed Zyprexa, a drug for schizophrenia and bipolar disorder, as a treatment for older patients with dementia, according to marketing materials.

Drug Company Suppressed $4.2 Billion Schizophrenia Drug's Dangers
Source: MarketWatch.com

TEL AVIV (MarketWatch) - Eli Lilly & Co.

Eli Lilly Promoted Drug Under False Pretenses
Source: NPR

Drug maker Eli Lilly & Co. used questionable marketing practices to promote its drug to fight blood infections, according to several doctors.

'Lost' producers lobby for scheduling change
Source: digitalspy.co.uk

The producers of LOST are not happy with the frequent reruns and breakups of the season, and are lobbying ABC for changes next year.

This area needs news. Click here to seed the vine